You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. LC-MS System to Determine the Molecular Mass of Synthesized Heparan and Chondroitin Sulfate Oligosaccharides

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: 300

    This fast-track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological research. Glycan Therapeutics is a biotech company specialized in synthesizing sulfated carbohydrates using innovative enzyme-based methods. This proposal is focused on the synthesis of large authentic oligosaccharides in the size range of 10-mers to ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A Comprehensive Newborn Screening Solution for Duchenne and Congenital Muscular Dystrophies

    SBC: BAEBIES, INC.            Topic: NICHD

    Congenital genetic abnormalities are a leading cause of childhood mortality and morbidity. While routine newborn screening (NBS) has dramatically improved health outcomes, many congenital disorders such as Duchenne muscular dystrophy (DMD) and other congenital muscular dystrophies (CMD) are not currently detected by routine NBS. Presymptomatic identification through NBS is critical to facilitate e ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. ALow Blood Volume Platform for Global Newborn Screening of Common, Treatable Conditions

    SBC: BAEBIES, INC.            Topic: NICHD

    An estimated 80% of babies born worldwide (approximately 100 million each year) currently do not receive any newborn screening care. Newborn screening (NBS) is an immensely successful testing program that identifies those at increased risk for common, treatable congenital disorders; the pre-symptomatic identification of these disorders in newborns enables the rapid initiation of treatments and red ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Advanced therapeutic for Parkinson's Disease

    SBC: Inhibikase Therapeutics, Inc.            Topic: 999

    Parkinsonandapos;s Disease (PD) is a progressive neurodegenerative disorder that affects ≈1 million patient in the U.S. annually and 7 to 10 million people worldwide. PD is characterized by disorders of movement, which are caused by the progressive loss of dopamine neurons in the substantia nigra pars compacta (SNpc), and autonomic dysfunction, anxiety, depression, sleep disorders and cognitive ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Online course to prepare promotores to support low-income Latino parents of children with special healthcare needs

    SBC: KDH Research & Communication, Inc.            Topic: 102

    KDH Research andamp; Communication (KDHRC) submits this Fast Track SBIR proposal to develop, implement, and rigorously evaluate a culturally competent, online professional development course to prepare promotores to support low-income Latino parents of children with special health care needs (CSHCN) as they navigate the education and health care systems. CSHCN experience poorer health, psychosocia ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia

    SBC: Arrevus, Inc.            Topic: NIAID

    Bloodstream infections (BSIs) caused by Gram-negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic-resistant nature of the pathogens. Infections caused by multi-drug resistant (MDR) bacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic options. This lack of treatment options is particularly ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Non-Invasive Physiologic Evaluation of Peripheral Arterial Disease

    SBC: RFPi, Inc.            Topic: NHLBI

    ABSTRACT Peripheral Arterial Disease (PAD) is a substantial healthcare burden in the US (estimated andgt; 8M) and around the world (estimated andgt; 200M). In the aging population, over 24% with age andgt; 80 years have PAD. 50% of all patients with PAD are asymptomatic, and up to 40% of the remaining patients have atypical symptoms. The conventional ankle/brachial index (cABI) ratio is establishe ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. System for faster microarray assays and end-to-end workflow automation

    SBC: Redbud Labs, Inc.            Topic: 400

    ABSTRACTMicroarrays are an important research tool (genomics and proteomics) and clinical tool (biomarker discovery and diagnosis). Current microarray processing methods are limited by slow assay kinetics, are not amenable to automation, and require high volume of expensive reagents/buffers. Miniaturization of these technologies has been explored to improve throughput. The demand for microarrays c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Multiplex Platform for Point-of-Care Newborn Screening of Hyperbilirubinemia

    SBC: BAEBIES, INC.            Topic: NICHD

    ABSTRACT Multiplex Platform for Point-of-Care Newborn Screening of Hyperbilirubinemia (SBIR Phase IIB) Hyperbilirubinemia (jaundice) affects more than half of all newborns and is typically benign if identified and treated promptly. Without proper treatment, high bilirubin leads to serious neurological dysfunction including neuro-motor, auditory, speech, cognition, and language disturbances. Rapid ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Novel enzyme inhibitor screening platform using modified designer nucleosomes

    SBC: Epicypher, Inc.            Topic: 300

    PROJECT SUMMARYChromatin function is regulated by reversible histone post-translational modifications (PTMs), including lysine methylation, acetylation, and monoubiquitination. Evidence places histone monoubiquitination (ub1) upstream of other chromatin PTMs, acting as a critical signaling center that regulates cascades of downstream epigenetic enzymes (e.g. histone methyltransferase enzymes or HM ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government